Form D · Biotechnology
ASURAGEN INC
Austin, TX · CIK 0001358480
Offering snapshot reported Mar 20, 2013 · SEC filing
- Reported sold
- $7.5M Offering amount: $15M
- Investors reported
- 15 Form D · investor count
- Minimum accepted
- $100K Reported outside-investor minimum
- First sale
- Mar 7, 2013 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Mar 20, 2013 | Initial | $7,500,000 | No comparison | 15 | SEC filing |
| Aug 11, 2011 | Initial | $5,000,000 | No comparison | 1 | SEC filing |
| Nov 19, 2007 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Mar 20, 2006 | Paper | Not reported | No comparison | Not reported |
Offering details
- Securities
- Equity
- Exemptions
- 06
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-193625
Source: Form D, filed Mar 20, 2013. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Lyle Arnold | Director |
| Carol Berry | Executive |
| Rolland Carlson | Director, Executive |
| Robert J Dominici | Director |
| Christopher D Earl | Director |
| Lynne Hohlfeld | Executive |
| Evan S Melrose | Director |
| John E Mooney | Director |
| David Rubin | Director |
| David Sargent | Director |
| Ana Ward | Executive |
| Matthew M Winkler | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
2150 Woodward Street Suite 100
Austin, TX, 78744
Austin, TX, 78744